28 / 74 · 1:03 · Original AXON film
LL-37
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Innate immune biology
LL-37 is a human antimicrobial peptide involved in innate defense. Researchers also study its effects on inflammation and wound biology, which makes the story more complex than a natural antibiotic label. [1]
Human trial | No significant overall benefit
A phase two-b trial tested topical LL-37 alongside compression care in 148 people with difficult venous leg ulcers. The overall study did not find a significant healing advantage over placebo. [1]
Post hoc subgroup finding
An analysis performed afterward suggested a signal in larger ulcers. That is a reason to test a hypothesis, not to replace the study’s overall result. [1]
Route and indication matter
Those findings also do not establish that injected LL-37 treats infections. FDA highlights safety uncertainty. A molecule’s normal role in the body cannot substitute for treatment evidence. [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Mahlapuu et al. (2021): Randomized phase IIb LL-37 venous-leg-ulcer trial →148 participants, no significant overall healing benefit, exploratory subgroup findings.
- FDA peptide safety information: Cathelicidin LL-37 →Safety uncertainty.
